CLAIMS

1. A compound which is an amide of the formula **(2)**:



(2)

or a salt or stereoisomer thereof; wherein:

R^7 is selected from chlorine and fluorine;

R^3, R^4, R^5 and R^6 are each independently selected from hydrogen, fluorine and chlorine;

n is 0, 1 or 2;

Q^1 is selected from C(=O), S(=O) and SO_2;

A is absent or is NR^2;

R^1 is selected from:

- hydrogen;
- a C_{1-6} non-aromatic hydrocarbon group optionally substituted with one or more substituents selected from hydroxyl, C_{1-2} alkoxy, amino, mono-C_{1-4} alkylamino, di-C_{1-4} alkylamino, 3- to 7-membered non-aromatic carbocyclic and heterocyclic rings containing one or two heteroatom ring members selected from O, N and S, and bridged bicyclic heterocyclic rings of seven to nine ring members of which one or two are nitrogen atoms, the carbocyclic and heterocyclic rings and bridged bicyclic heterocyclic rings being optionally substituted with one or more hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, C_{1-4} alkoxycarbonyl or hydroxyl-C_{1-3} alkyl groups; and
- 3- to 7-membered non-aromatic carbocyclic and heterocyclic rings containing one or two heteroatom ring members selected from O, N and S, and bridged bicyclic heterocyclic rings of seven to nine ring members of which one or two are nitrogen atoms, the carbocyclic and heterocyclic rings and bridged bicyclic heterocyclic rings being optionally substituted with one or more hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, C_{1-4} alkoxycarbonyl, amino-

C_{1-3}alkyl, mono-C_{1-2} alkylamino-C_{1-3} alkyl, di-C_{1-2} alkylamino-C_{1-3} alkyl or hydroxyl-C_{1-3} alkyl groups;

R^2 is selected from hydrogen and C_{1-4} alkyl; or

NR^1R^2 forms a 4- to 7-membered non-aromatic nitrogen-containing heterocyclic ring optionally containing a second heteroatom ring member selected from nitrogen and oxygen, the heterocyclic ring being optionally substituted with one or more hydroxy, C_{1-4} alkyl, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, C_{1-4} alkoxy, C_{1-4} alkoxycarbonyl amino-C_{1-3}alkyl, mono-C_{1-2} alkylamino-C_{1-3} alkyl, di-C_{1-2} alkylamino-C_{1-3} alkyl or hydroxy-C_{1-3} alkyl groups;

with the provisos that:

(i) no more than two of R^3 to R^6 are other than hydrogen; and

(ii) when R^7 and R^6 are both fluorine, then one of R^3 to R^5 is chlorine or fluorine and/or R^1-A-Q^1 is selected from ethylsulfonyl and isopropylsulfonyl.

2. A compound according to claim 1 provided that when R^7 and R^6 are both fluorine, then one of R^3 to R^5 is chlorine or fluorine.

3. A compound according to claim 1 wherein R^7 is chlorine.

4. A compound according to claim 3 wherein R^7 is chlorine and R^6 is fluorine.

5. A compound according to claim 3 wherein R^7 and R^6 are both chlorine.

6. A compound according to any one of claims 1 to 5 wherein at least one of R^3 and R^5 is hydrogen.

7. A compound according to any one of claims 1 to 6 wherein:

R^1 is selected from:

- hydrogen;
- a C_{1-3} alkyl group optionally substituted with one or more substituents selected from hydroxy, amino and methylamino; and
- 5 to 6-membered heterocyclic rings selected from pyrrolidine and piperidine, the heterocyclic rings being optionally substituted with a methyl group;

R^2, when present, is selected from hydrogen and methyl; or

NR^1R^2 forms a 5 to 6-membered heterocyclic ring selected from pyrrolidine and morpholine, the heterocyclic ring being optionally substituted with a hydroxymethyl group.

8. A compound according to any one of claims 1 to 7 wherein Q^1-A-R^1 is selected from groups AA, AG, AH, AI, AR, AS and AT in the table below:

 AA	 AG	 AH
 AI	 AS	 AT

wherein the point of attachment to the phenyl group is indicated by the asterisk.

9. A compound according to claim 8 which is selected from:
2-(2,6-dichloro-phenyl)-5-(4-methanesulfonyl-phenylamino)-oxazole-4-carboxylic acid amide;
2-(2-chloro-6-fluoro-phenyl)-5-(4-methanesulfonyl-phenylamino)-oxazole-4-carboxylic acid amide;
5-(4-methanesulfonyl-phenylamino)-2-(2,4,6-trifluoro-phenyl)-oxazole-4-carboxylic acid amide;
2-(2,5-difluoro-phenyl)-5-(4-methanesulfonyl-phenylamino)-oxazole-4-carboxylic acid amide;
(*S*) 2-(2-chloro-6-fluoro-phenyl)-5-[4-(piperidin-3-ylcarbamoyl)-phenylamino]-oxazole-4-carboxylic acid amide;
(*R*) 2-(2-chloro-6-fluoro-phenyl)-5-[4-(piperidin-3-ylcarbamoyl)-phenylamino]-oxazole-4-carboxylic acid amide;
2-(2-chloro-6-fluoro-phenyl)-5-[4-(morpholine-4-carbonyl)-phenylamino]-oxazole-4-carboxylic acid amide;
2-(2-chloro-6-fluoro-phenyl)-5-[4-(1-methyl-piperidin-4-ylcarbamoyl)-phenylamino]-oxazole-4-carboxylic acid amide;
(*S*) 2-(2,6-dichloro-phenyl)-5-[4-(piperidin-3-ylcarbamoyl)-phenylamino]-oxazole-4-carboxylic acid amide;
(*R*) 2-(2,6-dichloro-phenyl)-5-[4-(piperidin-3-ylcarbamoyl)-phenylamino]-oxazole-4-carboxylic acid amide;

2-(2,6-dichloro-phenyl)-5-[4-(morpholine-4-carbonyl)-phenylamino]-oxazole-4-carboxylic acid amide;
2-(2,6-dichloro-phenyl)-5-[4-(1-methyl-piperidin-4-ylcarbamoyl)-phenylamino]-oxazole-4-carboxylic acid amide;
2-(2,6-difluoro-phenyl)-5-(4-ethanesulfonyl-phenylamino)-oxazole-4-carboxylic acid amide;
2-(2,6-difluoro-phenyl)-5-(4-methanesulfonyl-phenylamino)-oxazole-4-carboxylic acid amide; and
2-(2,6-difluoro-phenyl)-5-[4-propane-2-sulfonyl)-henylamino]-oxazole-4-carboxylic acid amide;
and salts and stereoisomers thereof.

10. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 9 and a pharmaceutically acceptable excipient.

11. A compound according to any one of claims 1 to 9 for use in medicine.

12. A compound for use in a method of inhibiting a TYK2 kinase, which method comprises bringing into contact with the TYK2 kinase an effective TYK2 kinase-inhibiting amount of the compound, wherein the compound has the formula **(0)**:



(0)

or is a salt or stereoisomer thereof; wherein:
n is 0, 1 or 2;
Ar^1 is selected from phenyl, pyridyl, thienyl and furanyl, each of which is optionally substituted with one, two or three substituents independently selected from halogen, C_{1-4} alkyl, hydroxyl-C_{1-4} alkyl, C_{1-2} alkoxy-C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-2} alkoxy-C_{1-4} alkoxy, C_{2-4} alkenyl, C_{2-4} alkenyloxy, C_{2-4} alkynyl, C_{2-4} alkynyloxy, cyano, C_{1-4} alkanoyl, hydroxy and C_{1-4} alkanoyloxy, wherein the C_{1-4} alkyl and

C_{1-4} alkoxy moieties are each optionally substituted with one or more fluorine atoms;

Q^1 is selected from C(=O), S(=O) and SO_2;

A is absent or is NR^2;

R^1 is selected from:

- hydrogen;
- a C_{1-6} non-aromatic hydrocarbon group optionally substituted with one or more substituents selected from hydroxyl, C_{1-2} alkoxy, amino, mono-C_{1-4} alkylamino, di-C_{1-4} alkylamino, 3- to 7-membered non-aromatic carbocyclic and heterocyclic rings containing one or two heteroatom ring members selected from O, N and S, and bridged bicyclic heterocyclic rings of seven to nine ring members of which one or two are nitrogen atoms, the carbocyclic and heterocyclic rings and bridged bicyclic heterocyclic rings being optionally substituted with one or more hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, C_{1-4} alkoxycarbonyl or hydroxyl-C_{1-3} alkyl groups; and
- 3- to 7-membered non-aromatic carbocyclic and heterocyclic rings containing one or two heteroatom ring members selected from O, N and S, and bridged bicyclic heterocyclic rings of seven to nine ring members of which one or two are nitrogen atoms, the carbocyclic and heterocyclic rings and bridged bicyclic heterocyclic rings being optionally substituted with one or more hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, C_{1-4} alkoxycarbonyl, amino-C_{1-3}alkyl, mono-C_{1-2} alkylamino-C_{1-3} alkyl, di-C_{1-2} alkylamino-C_{1-3} alkyl or hydroxyl-C_{1-3} alkyl groups;

R^2 is selected from hydrogen and C_{1-4} alkyl; or

NR^1R^2 forms a 4- to 7-membered non-aromatic nitrogen-containing heterocyclic ring optionally containing a second heteroatom ring member selected from nitrogen and oxygen, the heterocyclic ring being optionally substituted with one or more hydroxy, C_{1-4} alkyl, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, C_{1-4} alkoxy, C_{1-4} alkoxycarbonyl amino-C_{1-3}alkyl, mono-C_{1-2} alkylamino-C_{1-3} alkyl, di-C_{1-2} alkylamino-C_{1-3} alkyl or hydroxy-C_{1-3} alkyl groups.

13. A compound for use according to claim 12 wherein the compound has the formula (1):



(1)

or a salt or stereoisomer thereof; wherein:

Ar^1 is selected from phenyl, pyridyl, thienyl and furanyl, each of which is optionally substituted with one, two or three substituents independently selected from halogen, C_{1-4} alkyl, hydroxyl-C_{1-4} alkyl, C_{1-2} alkoxy-C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-2} alkoxy-C_{1-4} alkoxy, C_{2-4} alkenyl, C_{2-4} alkenyloxy, C_{2-4} alkynyl, C_{2-4} alkynyloxy, cyano, C_{1-4} alkanoyl, hydroxy and C_{1-4} alkanoyloxy, wherein the C_{1-4} alkyl and C_{1-4} alkoxy moieties are each optionally substituted with one or more fluorine atoms;

Q^1 is selected from C(=O), S(=O) and SO_2;

A is absent or is NR^2;

R^1 is selected from:

- hydrogen;
- a C_{1-6} non-aromatic hydrocarbon group optionally substituted with one or more substituents selected from hydroxyl, C_{1-2} alkoxy, amino, mono-C_{1-4} alkylamino, di-C_{1-4} alkylamino, 3- to 7-membered non-aromatic carbocyclic and heterocyclic rings containing one or two heteroatom ring members selected from O, N and S, and bridged bicyclic heterocyclic rings of seven to nine ring members of which one or two are nitrogen atoms, the carbocyclic and heterocyclic rings and bridged bicyclic heterocyclic rings being optionally substituted with one or more hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, C_{1-4} alkoxycarbonyl or hydroxyl-C_{1-3} alkyl groups; and
- 3- to 7-membered non-aromatic carbocyclic and heterocyclic rings containing one or two heteroatom ring members selected from O, N and S, and bridged bicyclic heterocyclic rings of seven to nine ring members of which one or two are nitrogen atoms, the carbocyclic and heterocyclic rings and bridged bicyclic heterocyclic rings being optionally substituted with one or more hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, C_{1-4} alkoxycarbonyl, amino-

C_{1-3}alkyl, mono-C_{1-2} alkylamino-C_{1-3} alkyl, di-C_{1-2} alkylamino-C_{1-3} alkyl or hydroxyl-C_{1-3} alkyl groups;

R^2 is selected from hydrogen and C_{1-4} alkyl; or

NR^1R^2 forms a 4- to 7-membered non-aromatic nitrogen-containing heterocyclic ring optionally containing a second heteroatom ring member selected from nitrogen and oxygen, the heterocyclic ring being optionally substituted with one or more hydroxy, C_{1-4} alkyl, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, C_{1-4} alkoxy, C_{1-4} alkoxycarbonyl amino-C_{1-3}alkyl, mono-C_{1-2} alkylamino-C_{1-3} alkyl, di-C_{1-2} alkylamino-C_{1-3} alkyl or hydroxy-C_{1-3} alkyl groups.

14. A compound for use according to claim 13 wherein the compound of formula (1) is selected from:

2-(2,6-difluorophenyl)-5-(4-(methylsulfonyl)phenylamino)oxazole-4-carboxamide;

2-(2,6-difluorophenyl)-5-(4-sulfamoylphenylamino)oxazole-4-carboxamide;

2-(2,6-difluorophenyl)-5-(4-(N,N-dimethylsulfamoyl)phenylamino)oxazole-4-carboxamide;

2-(2,6-difluorophenyl)-5-(4-(N'-methylsulfamoyl)phenylamino)oxazole-4-carboxamide;

2-(2,6-difluorophenyl)-5-(4-(dimethylcarbamoyl)phenylamino)oxazole-4-carboxamide;

5-(4-((3-aminopropyl)carbamoyl)phenylamino)-2-(2,6-difluorophenyl)oxazole-4-carboxamide;

(R)-2-(2,6-difluorophenyl)-5-(4-(piperidin-3-ylcarbamoyl)phenylamino)oxazole-4-carboxamide;

(S)-2-(2,6-difluorophenyl)-5-(4-(piperidin-3-ylcarbamoyl)phenylamino)oxazole-4-carboxamide;

2-(2,6-difluorophenyl)-5-(4-(morpholine-4-carbonyl)phenylamino)oxazole-4-carboxamide;

5-(4-((2-(methylamino)ethyl)carbamoyl)phenylamino)-2-(2,6-difluorophenyl) oxazole-4-carboxamide;

5-(4-((3-(methylamino)propyl)carbamoyl)phenylamino)-2-(2,6-difluorophenyl) oxazole-4-carboxamide;

(R)-2-(2,6-difluorophenyl)-5-(4-(pyrrolidin-3-ylcarbamoyl)phenylamino)oxazole-4-carboxamide;

(S)-2-(2,6-difluorophenyl)-5-(4-(pyrrolidin-3-ylcarbamoyl)phenylamino)oxazole-4-carboxamide;

(R)-2-(2,6-difluorophenyl)-5-(4-(2-(hydroxymethyl)pyrrolidine-1-carbonyl) phenylamino)oxazole-4-carboxamide;
5-(4-((2-hydroxyethyl)carbamoyl)phenylamino)-2-(2,6-difluorophenyl)oxazole-4-carboxamide;
5-(4-((3-hydroxypropyl)carbamoyl)phenylamino)-2-(2,6-difluorophenyl)oxazole-4-carboxamide;
2-(2,6-difluorophenyl)-5-(4-(piperidin-4-ylcarbamoyl)phenylamino)oxazole-4-carboxamide; and
5-(4-((1-methylpiperidin-4-yl)carbamoyl)phenylamino)-2-(2,6-difluorophenyl) oxazole-4-carboxamide;
and salts thereof.

15. A compound as defined in any one of claims 1 to 9 and 12 to 14 for use in:
(A) a method of treating a disease or condition in a subject in need thereof, wherein the disease is selected from an inflammatory disease or condition, an immunological disease or condition, an allergic disease or disorder, a transplant rejection and Graft-versus host disease wherein the disease or condition is susceptible to TYK2 inhibition, which method comprises administering to the subject an effective TYK2 inhibiting amount of the compound; or
(B) a method of treating an autoimmune disease in a subject in need thereof, which method comprises administering to the subject an effective TYK2 inhibiting amount of the compound so as to inhibit TYK2 kinase in the subject and thereby block or reduce the extent of an inflammatory process associated with the autoimmune disease; or
(C) a method of treating a disease or condition in a subject in need thereof, wherein the disease is other than an autoimmune disease and is selected from an inflammatory disease or condition, an immunological disease or condition, an allergic disease or disorder, a transplant rejection and Graft-versus host disease wherein the disease or condition is susceptible to TYK2 inhibition, which method comprises administering to the subject an effective TYK2 inhibiting amount of the compound; or
(D) a method of treating a disease or condition in a subject in need thereof, wherein the disease is any one or more diseases or conditions selected from:
(a) skin inflammation due to radiation exposure;
(b) asthma;
(c) allergic inflammation;

(d) chronic inflammation;

(e) an inflammatory ophthalmic disease;

(f) dry eye syndrome (DES, also known as keratoconjunctivitis sicca or dysfunctional tear syndrome);

(g) uveitis (e.g. chronic progressive or relapsing forms of non-infectious uveitis);

(h) insulin- dependent diabetes (Type I);

(i) Hashimoto's thyroiditis;

(j) Graves' disease;

(k) Cushing's disease;

(l) Addison's disease (which affect the adrenal glands)

(m) chronic active hepatitis (which affects the liver);

(n) polycystic ovary syndrome (PCOS);

(o) coeliac disease;

(p) psoriasis;

(q) inflammatory bowel disease (IBD);

(r) ankylosing spondylitis;

(s) rheumatoid arthritis;

(t) systemic lupus erythematosus;

(u) myasthenia gravis;

(v) transplant rejection (allograft transplant rejection); and

(w) graft-versus-host disease (GVDH);

wherein the disease is optionally further selected from:

(x) sepsis and septic shock; and

(y) multiple sclerosis;

which method comprises administering to the subject an effective TYK2 inhibiting amount of the compound; or

(E) the diagnosis and treatment of a disease state or condition mediated by TYK2 kinase, which diagnosis and treatment comprises (i) screening a patient to determine whether a disease or condition from which the patient is or may be suffering is one which would be susceptible to treatment with a compound having activity against the kinase; and (ii) where it is indicated that the disease or condition from which the patient is thus susceptible, thereafter administering to the patient an effective TYK2 inhibiting amount of the compound.

CLAIMS

1. A compound which is an amide of the formula **(2)**:



(2)

or a salt or stereoisomer thereof; wherein:

R^7 is selected from chlorine and fluorine;

R^3, R^4, R^5 and R^6 are each independently selected from hydrogen, fluorine and chlorine;

n is 0, 1 or 2;

Q^1 is selected from C(=O), S(=O) and SO_2;

A is absent or is NR^2;

R^1 is selected from:

- hydrogen;
- a C_{1-3} alkyl group optionally substituted with one or more substituents selected from hydroxy, amino and methylamino; and
- 5 to 6-membered heterocyclic rings selected from pyrrolidine and piperidine, the heterocyclic rings being optionally substituted with a methyl group;

R^2, when present, is selected from hydrogen and methyl; or

NR^1R^2 forms a 5 to 6-membered heterocyclic ring selected from pyrrolidine and morpholine, the heterocyclic ring being optionally substituted with a hydroxymethyl group;

with the provisos that:

(i) no more than two of R^3 to R^6 are other than hydrogen; and

(ii) when R^7 and R^6 are both fluorine, then one of R^3 to R^5 is chlorine or fluorine and/or R^1-A-Q^1 is selected from ethylsulfonyl and isopropylsulfonyl.

2. A compound according to claim 1 provided that when R^7 and R^6 are both fluorine, then one of R^3 to R^5 is chlorine or fluorine.

3. A compound according to claim 1 wherein R^7 is chlorine.

4. A compound according to claim 3 wherein R^7 is chlorine and R^6 is fluorine.

5. A compound according to claim 3 wherein R^7 and R^6 are both chlorine.

6. A compound according to any one of claims 1 to 5 wherein at least one of R^3 and R^5 is hydrogen.

7. A compound according to claim 6 wherein R^3, R^4 and R^5 are hydrogen.

8. A compound according to any one of claims 1 to 7 wherein Q^1 is C(=O).

9. A compound according to claim 8 wherein A is NR^2 and NR^1R^2 forms a 5 to 6-membered heterocyclic ring selected from pyrrolidine and morpholine, the heterocyclic ring being optionally substituted with a hydroxymethyl group.

10. A compound according to any one of claims 1 to 7 wherein A is absent; Q^1 is SO_2 and R^1 is a C_{1-3} alkyl group.

11. A compound according to any one of claims 1 to 7 wherein Q^1-A-R^1 is selected from groups AA, AG, AH, AI, AR, AS and AT in the table below:

 AA	 AG	 AH
 AI	 AR	 AS
 AT		

wherein the point of attachment to the phenyl group is indicated by the asterisk.

12. A compound according to claim 1 which is selected from:
2-(2,6-dichloro-phenyl)-5-(4-methanesulfonyl-phenylamino)-oxazole-4-carboxylic acid amide;

2-(2-chloro-6-fluoro-phenyl)-5-(4-methanesulfonyl-phenylamino)-oxazole-4-carboxylic acid amide;
5-(4-methanesulfonyl-phenylamino)-2-(2,4,6-trifluoro-phenyl)-oxazole-4-carboxylic acid amide;
2-(2,5-difluoro-phenyl)-5-(4-methanesulfonyl-phenylamino)-oxazole-4-carboxylic acid amide;
(*S*) 2-(2-chloro-6-fluoro-phenyl)-5-[4-(piperidin-3-ylcarbamoyl)-phenylamino]-oxazole-4-carboxylic acid amide;
(*R*) 2-(2-chloro-6-fluoro-phenyl)-5-[4-(piperidin-3-ylcarbamoyl)-phenylamino]-oxazole-4-carboxylic acid amide;
2-(2-chloro-6-fluoro-phenyl)-5-[4-(morpholine-4-carbonyl)-phenylamino]-oxazole-4-carboxylic acid amide;
2-(2-chloro-6-fluoro-phenyl)-5-[4-(1-methyl-piperidin-4-ylcarbamoyl)-phenylamino]-oxazole-4-carboxylic acid amide;
(*S*) 2-(2,6-dichloro-phenyl)-5-[4-(piperidin-3-ylcarbamoyl)-phenylamino]-oxazole-4-carboxylic acid amide;
(*R*) 2-(2,6-dichloro-phenyl)-5-[4-(piperidin-3-ylcarbamoyl)-phenylamino]-oxazole-4-carboxylic acid amide;
2-(2,6-dichloro-phenyl)-5-[4-(morpholine-4-carbonyl)-phenylamino]-oxazole-4-carboxylic acid amide;
2-(2,6-dichloro-phenyl)-5-[4-(1-methyl-piperidin-4-ylcarbamoyl)-phenylamino]-oxazole-4-carboxylic acid amide;
2-(2,6-difluoro-phenyl)-5-(4-ethanesulfonyl-phenylamino)-oxazole-4-carboxylic acid amide; and
2-(2,6-difluoro-phenyl)-5-[4-propane-2-sulfonyl)-henylamino]-oxazole-4-carboxylic acid amide;
and salts and stereoisomers thereof.

13. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 12 and a pharmaceutically acceptable excipient.

14. A compound according to any one of claims 1 to 12 for use in medicine.

15. The use of a compound according to any one of claims 1 to 12, or a salt thereof, in the manufacture of a medicament for :
(A) the treatment of a disease or condition in a subject in need thereof, wherein the disease is selected from an inflammatory disease or condition, an immunological disease or condition, an allergic disease or disorder, a transplant

rejection and Graft-versus host disease wherein the disease or condition is susceptible to TYK2 inhibition, which method comprises administering to the subject an effective TYK2 inhibiting amount of the compound; or

(B) the treatment of an autoimmune disease in a subject in need thereof, which method comprises administering to the subject an effective TYK2 inhibiting amount of the compound so as to inhibit TYK2 kinase in the subject and thereby block or reduce the extent of an inflammatory process associated with the autoimmune disease; or

(C) the treatment of a disease or condition in a subject in need thereof, wherein the disease is other than an autoimmune disease and is selected from an inflammatory disease or condition, an immunological disease or condition, an allergic disease or disorder, a transplant rejection and Graft-versus host disease wherein the disease or condition is susceptible to TYK2 inhibition, which method comprises administering to the subject an effective TYK2 inhibiting amount of the compound; or

(D) the treatment of a disease or condition in a subject in need thereof, wherein the disease is any one or more diseases or conditions selected from:

(a) skin inflammation due to radiation exposure;

(b) asthma;

(c) allergic inflammation;

(d) chronic inflammation;

(e) an inflammatory ophthalmic disease;

(f) dry eye syndrome (DES, also known as keratoconjunctivitis sicca or dysfunctional tear syndrome);

(g) uveitis (e.g. chronic progressive or relapsing forms of non-infectious uveitis);

(h) insulin- dependent diabetes (Type I);

(i) Hashimoto's thyroiditis;

(j) Graves' disease;

(k) Cushing's disease;

(l) Addison's disease (which affect the adrenal glands)

(m) chronic active hepatitis (which affects the liver);

(n) polycystic ovary syndrome (PCOS);

(o) coeliac disease;

(p) psoriasis;

(q) inflammatory bowel disease (IBD);

(r) ankylosing spondylitis;

(s) rheumatoid arthritis;

(t) systemic lupus erythematosus;

(u) myasthenia gravis;

(v) transplant rejection (allograft transplant rejection); and

(w) graft-versus-host disease (GVDH);

wherein the disease is optionally further selected from:

(x) sepsis and septic shock; and

(y) multiple sclerosis;

which method comprises administering to the subject an effective TYK2 inhibiting amount of the compound; or

(E) the diagnosis and treatment of a disease state or condition mediated by TYK2 kinase, which diagnosis and treatment comprises (i) screening a patient to determine whether a disease or condition from which the patient is or may be suffering is one which would be susceptible to treatment with a compound having activity against the kinase; and (ii) where it is indicated that the disease or condition from which the patient is thus susceptible, thereafter administering to the patient an effective TYK2 inhibiting amount of the compound.